151 related articles for article (PubMed ID: 17700543)
1. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells.
Hong SH; Jeong JS; Lee YJ; Jung HI; Cho KS; Kim CM; Kwon BS; Sullenger BA; Lee SW; Kim IH
Mol Ther; 2008 Jan; 16(1):74-80. PubMed ID: 17700543
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model.
Jeong JS; Lee SW; Hong SH; Lee YJ; Jung HI; Cho KS; Seo HH; Lee SJ; Park S; Song MS; Kim CM; Kim IH
Clin Cancer Res; 2008 Jan; 14(1):281-90. PubMed ID: 18172280
[TBL] [Abstract][Full Text] [Related]
3. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW
Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435
[TBL] [Abstract][Full Text] [Related]
4. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme.
Song MS; Jeong JS; Cho KS; Lee SW
Exp Mol Med; 2007 Dec; 39(6):722-32. PubMed ID: 18160843
[TBL] [Abstract][Full Text] [Related]
5. In vivo reprogramming of human telomerase reverse transcriptase (hTERT) by trans-splicing ribozyme to target tumor cells.
Lee SJ; Lee SW; Jeong JS; Kim IH
Methods Mol Biol; 2010; 629():307-21. PubMed ID: 20387158
[TBL] [Abstract][Full Text] [Related]
6. Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement.
Won YS; Jeong JS; Kim SJ; Ju MH; Lee SW
Cancer Lett; 2015 Jan; 356(2 Pt B):918-28. PubMed ID: 25444904
[TBL] [Abstract][Full Text] [Related]
7. Intracellular efficacy of tumor-targeting group I intron-based trans-splicing ribozyme.
Kwon BS; Jeong JS; Won YS; Lee CH; Yoon KS; Hyung Jung M; Kim IH; Lee SW
J Gene Med; 2011 Feb; 13(2):89-100. PubMed ID: 21322101
[TBL] [Abstract][Full Text] [Related]
8. Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme.
Song MS; Lee SW
FEBS Lett; 2006 Sep; 580(21):5033-43. PubMed ID: 16949075
[TBL] [Abstract][Full Text] [Related]
9. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript.
Kwon BS; Jung HS; Song MS; Cho KS; Kim SC; Kimm K; Jeong JS; Kim IH; Lee SW
Mol Ther; 2005 Nov; 12(5):824-34. PubMed ID: 16040278
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific induction of adenoviral E1A expression by group I intron-based trans-splicing ribozyme.
Won YS; Lee SW
J Microbiol Biotechnol; 2012 Mar; 22(3):431-5. PubMed ID: 22450801
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
Gu J; Kagawa S; Takakura M; Kyo S; Inoue M; Roth JA; Fang B
Cancer Res; 2000 Oct; 60(19):5359-64. PubMed ID: 11034071
[TBL] [Abstract][Full Text] [Related]
12. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.
Kim E; Kim JH; Shin HY; Lee H; Yang JM; Kim J; Sohn JH; Kim H; Yun CO
Hum Gene Ther; 2003 Oct; 14(15):1415-28. PubMed ID: 14577922
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging of endogenous mRNA expression in a mouse tumor model by adenovirus harboring trans-splicing ribozyme.
Hong SH; Jeong JS; Lee YJ; Jung HI; Kim KT; Kim YH; Lee YS; Lee SW; Bae CD; Park J; Kim IH
FEBS Lett; 2007 Nov; 581(28):5396-400. PubMed ID: 17976379
[TBL] [Abstract][Full Text] [Related]
14. Selective expression of transgene using hypoxia-inducible trans-splicing group I intron ribozyme.
Kim SJ; Lee SW
J Biotechnol; 2014 Dec; 192 Pt A():22-7. PubMed ID: 25312327
[TBL] [Abstract][Full Text] [Related]
15. Image-aided Suicide Gene Therapy Utilizing Multifunctional hTERT-targeting Adenovirus for Clinical Translation in Hepatocellular Carcinoma.
Kim YH; Kim KT; Lee SJ; Hong SH; Moon JY; Yoon EK; Kim S; Kim EO; Kang SH; Kim SK; Choi SI; Goh SH; Kim D; Lee SW; Ju MH; Jeong JS; Kim IH
Theranostics; 2016; 6(3):357-68. PubMed ID: 26909111
[TBL] [Abstract][Full Text] [Related]
16. Use of tumor-targeting trans-splicing ribozyme for cancer treatment.
Lee SW; Jeong JS
Methods Mol Biol; 2014; 1103():83-95. PubMed ID: 24318888
[TBL] [Abstract][Full Text] [Related]
17. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
18. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
[TBL] [Abstract][Full Text] [Related]
19. Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through MicroRNA Regulation.
Kim J; Won R; Ban G; Ju MH; Cho KS; Young Han S; Jeong JS; Lee SW
Sci Rep; 2015 Jul; 5():12315. PubMed ID: 26189916
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
